Advertisement

Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease

  • Akshay Shetty
  • Jennifer W. Hsu
  • Paul P. Manka
  • Wing-Kin Syn
Review

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in industrialized nations and is strongly associated with the metabolic syndrome. The prevalence of NAFLD continues to rise along with the epidemic of the metabolic syndrome. Metabolic homeostasis is linked to the circadian clock (rhythm), with multiple signaling pathways in organs regulated by circadian clock genes, and recent studies of circadian clock gene functions suggest that disruption of the circadian rhythm is associated with significant morbidity and mortality, including the metabolic syndrome. In the industrialized world, various human behaviors and activities such as work and eating patterns, jet lag, and sleep deprivation interfere with the circadian rhythm, leading to perturbations in metabolism and development of the metabolic syndrome. In this review, we discuss how disruption of the circadian rhythm is associated with various metabolic conditions that comprise the metabolic syndrome and NAFLD.

Keywords

Circadian rhythm Fatty liver Nonalcoholic steatohepatitis Obesity Diabetes mellitus 

Notes

Acknowledgments

Figures were created with “Biological illustration” (http://smart.servier.com) by Servier, used under Creative Commons Attribution 3.0 Unported License, and modified by Akshay Shetty and Paul Manka.

Funding

Resources were provided by the Ralph H Johnson VAMC, Charleston, South Carolina.

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. 2016;20:205–214.PubMedCrossRefGoogle Scholar
  2. 2.
    Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis. 2007;11:105–117, ix.PubMedCrossRefGoogle Scholar
  3. 3.
    Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology (Baltimore, MD). 2014;59:1174–1197.CrossRefGoogle Scholar
  4. 4.
    Wong RJ, Ahmed A. Obesity and nonalcoholic fatty liver disease: disparate associations among Asian populations. World J Hepatol. 2014;6:263–273.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Kanwar P, Kowdley KV. The metabolic syndrome and its influence on nonalcoholic steatohepatitis. Clin Liver Dis. 2016;20:225–243.PubMedCrossRefGoogle Scholar
  6. 6.
    Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114:842–845.PubMedCrossRefGoogle Scholar
  7. 7.
    Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014;15:8591–8638.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of nonalcoholic fatty liver disease (NAFLD). Metab Clin Exp. 2016;65:1038–1048.PubMedCrossRefGoogle Scholar
  9. 9.
    Harper DG, Volicer L, Stopa EG, McKee AC, Nitta M, Satlin A. Disturbance of endogenous circadian rhythm in aging and Alzheimer disease. Am J Geriatr Psychiatry. 2005;13:359–368.PubMedCrossRefGoogle Scholar
  10. 10.
    Wang F, Yeung KL, Chan WC, et al. A meta-analysis on dose–response relationship between night shift work and the risk of breast cancer. Ann Oncol. 2013;24:2724–2732.PubMedCrossRefGoogle Scholar
  11. 11.
    Wang F, Zhang L, Zhang Y, et al. Meta-analysis on night shift work and risk of metabolic syndrome. Obes Rev. 2014;15:709–720.PubMedCrossRefGoogle Scholar
  12. 12.
    Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002;418:935–941.PubMedCrossRefGoogle Scholar
  13. 13.
    Hirota T, Fukada Y. Resetting mechanism of central and peripheral circadian clocks in mammals. Zool Sci. 2004;21:359–368.PubMedCrossRefGoogle Scholar
  14. 14.
    Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science (New York, N.Y.). 2002;295:1070–1073.CrossRefGoogle Scholar
  15. 15.
    Yamazaki S, Numano R, Abe M, et al. Resetting central and peripheral circadian oscillators in transgenic rats. Science (New York, N.Y.). 2000;288:682–685.CrossRefGoogle Scholar
  16. 16.
    Damiola F, Le Minh N, Preitner N, Kornmann B, Fleury-Olela F, Schibler U. Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. Genes Dev. 2000;14:2950–2961.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Mendoza J, Graff C, Dardente H, Pevet P, Challet E. Feeding cues alter clock gene oscillations and photic responses in the suprachiasmatic nuclei of mice exposed to a light/dark cycle. J Neurosci. 2005;25:1514–1522.PubMedCrossRefGoogle Scholar
  18. 18.
    Ackermann K, Plomp R, Lao O, et al. Effect of sleep deprivation on rhythms of clock gene expression and melatonin in humans. Chronobiol Int. 2013;30:901–909.PubMedCrossRefGoogle Scholar
  19. 19.
    Cedernaes J, Osler ME, Voisin S, et al. Acute sleep loss induces tissue-specific epigenetic and transcriptional alterations to circadian clock genes in men. J Clin Endocrinol Metab. 2015;100:E1255–E1261.PubMedCrossRefGoogle Scholar
  20. 20.
    Potter GD, Skene DJ, Arendt J, Cade JE, Grant PJ, Hardie LJ. Circadian rhythm and sleep disruption: causes, metabolic consequences, and countermeasures. Endocr Rev. 2016;37:584–608.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Young MW, Kay SA. Time zones: a comparative genetics of circadian clocks. Nat Rev Genet. 2001;2:702–715.PubMedCrossRefGoogle Scholar
  22. 22.
    Brown SA. Circadian rhythms. A new histone code for clocks? Science (New York, N.Y.). 2011;333:1833–1834.CrossRefGoogle Scholar
  23. 23.
    Brown SA, Kowalska E, Dallmann R. (Re)inventing the circadian feedback loop. Dev Cell. 2012;22:477–487.PubMedCrossRefGoogle Scholar
  24. 24.
    Preitner N, Damiola F, Lopez-Molina L, et al. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell. 2002;110:251–260.PubMedCrossRefGoogle Scholar
  25. 25.
    Sato TK, Panda S, Miraglia LJ, et al. A functional genomics strategy reveals Rora as a component of the mammalian circadian clock. Neuron. 2004;43:527–537.PubMedCrossRefGoogle Scholar
  26. 26.
    Canaple L, Rambaud J, Dkhissi-Benyahya O, et al. Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-activated receptor alpha defines a novel positive feedback loop in the rodent liver circadian clock. Mol Endocrinol (Baltimore, MD). 2006;20:1715–1727.CrossRefGoogle Scholar
  27. 27.
    Crumbley C, Wang Y, Banerjee S, Burris TP. Regulation of expression of citrate synthase by the retinoic acid receptor-related orphan receptor alpha (RORalpha). PLoS ONE. 2012;7:e33804.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Billon C, Sitaula S, Burris TP. Metabolic characterization of a novel RORalpha knockout mouse model without Ataxia. Front Endocrinol. 2017;8:141.CrossRefGoogle Scholar
  29. 29.
    Akashi M, Tsuchiya Y, Yoshino T, Nishida E. Control of intracellular dynamics of mammalian period proteins by casein kinase I epsilon (CKIepsilon) and CKIdelta in cultured cells. Mol Cell Biol. 2002;22:1693–1703.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Marcheva B, Ramsey KM, Affinati A, Bass J. Clock genes and metabolic disease. J Appl Physiol (Bethesda, MD, 1985). 2009;107:1638–1646.CrossRefGoogle Scholar
  31. 31.
    Lamia KA, Sachdeva UM, DiTacchio L, et al. AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. Science (New York, NY). 2009;326:437–440.CrossRefGoogle Scholar
  32. 32.
    Moller N, Jorgensen JO, Schmitz O, et al. Effects of a growth hormone pulse on total and forearm substrate fluxes in humans. Am J Physiol. 1990;258:E86–E91.PubMedCrossRefGoogle Scholar
  33. 33.
    Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30:152–177.PubMedCrossRefGoogle Scholar
  34. 34.
    Linkowski P, Mendlewicz J, Kerkhofs M, et al. 24-Hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: effect of antidepressant treatment. J Clin Endocrinol Metab. 1987;65:141–152.PubMedCrossRefGoogle Scholar
  35. 35.
    Linkowski P, Kerkhofs M, Van Onderbergen A, et al. The 24-hour profiles of cortisol, prolactin, and growth hormone secretion in mania. Arch Gen Psychiatry. 1994;51:616–624.PubMedCrossRefGoogle Scholar
  36. 36.
    Ho KY, Veldhuis JD, Johnson ML, et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Investig. 1988;81:968–975.PubMedCrossRefGoogle Scholar
  37. 37.
    Vakili H, Jin Y, Cattini PA. Evidence for a circadian effect on the reduction of human growth hormone gene expression in response to excess caloric intake. J Biol Chem. 2016;291:13823–13833.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Brown GM. Light, melatonin and the sleep–wake cycle. J Psychiatry Neurosci. 1994;19:345–353.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Moore RY. Neural control of the pineal gland. Behav Brain Res. 1996;73:125–130.PubMedCrossRefGoogle Scholar
  40. 40.
    Klein DC. Arylalkylamine N-acetyltransferase: “the Timezyme”. J Biol Chem. 2007;282:4233–4237.PubMedCrossRefGoogle Scholar
  41. 41.
    Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41:89–94.PubMedCrossRefGoogle Scholar
  42. 42.
    Prokopenko I, Langenberg C, Florez JC, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41:77–81.PubMedCrossRefGoogle Scholar
  43. 43.
    Lane JM, Chang AM, Bjonnes AC, et al. Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology. Diabetes. 2016;65:1741–1751.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Tuomi T, Nagorny CL, Singh P, et al. Increased melatonin signaling is a risk factor for type 2 diabetes. Cell Metab. 2016;23:1067–1077.PubMedCrossRefGoogle Scholar
  45. 45.
    Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature. 1996;382:250–252.PubMedCrossRefGoogle Scholar
  46. 46.
    Bodosi B, Gardi J, Hajdu I, Szentirmai E, Obal F Jr, Krueger JM. Rhythms of ghrelin, leptin, and sleep in rats: effects of the normal diurnal cycle, restricted feeding, and sleep deprivation. Am J Physiol Regul Integr Comp Physiol. 2004;287:R1071–R1079.PubMedCrossRefGoogle Scholar
  47. 47.
    Ando H, Kumazaki M, Motosugi Y, et al. Impairment of peripheral circadian clocks precedes metabolic abnormalities in ob/ob mice. Endocrinology. 2011;152:1347–1354.PubMedCrossRefGoogle Scholar
  48. 48.
    Hwang CS, Mandrup S, MacDougald OA, Geiman DE, Lane MD. Transcriptional activation of the mouse obese (ob) gene by CCAAT/enhancer binding protein alpha. Proc Natl Acad Sci USA. 1996;93:873–877.PubMedCrossRefGoogle Scholar
  49. 49.
    Hollenberg AN, Susulic VS, Madura JP, et al. Functional antagonism between CCAAT/Enhancer binding protein-alpha and peroxisome proliferator-activated receptor-gamma on the leptin promoter. J Biol Chem. 1997;272:5283–5290.PubMedCrossRefGoogle Scholar
  50. 50.
    Kettner NM, Mayo SA, Hua J, Lee C, Moore DD, Fu L. Circadian dysfunction induces leptin resistance in mice. Cell Metab. 2015;22:448–459.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004;141:846–850.PubMedCrossRefGoogle Scholar
  52. 52.
    Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA. 2009;106:4453–4458.PubMedCrossRefGoogle Scholar
  53. 53.
    Haus E. Chronobiology in the endocrine system. Adv Drug Deliv Rev. 2007;59:985–1014.PubMedCrossRefGoogle Scholar
  54. 54.
    Kalsbeek A, Fliers E. Daily regulation of hormone profiles. Handb Exp Pharmacol. 2013;217:185–226.CrossRefGoogle Scholar
  55. 55.
    Sviridonova MA, Fadeyev VV, Sych YP, Melnichenko GA. Clinical significance of TSH circadian variability in patients with hypothyroidism. Endocr Res. 2013;38:24–31.PubMedCrossRefGoogle Scholar
  56. 56.
    Aninye IO, Matsumoto S, Sidhaye AR, Wondisford FE. Circadian regulation of Tshb gene expression by Rev-Erbalpha (NR1D1) and nuclear corepressor 1 (NCOR1). J Biol Chem. 2014;289:17070–17077.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Chawla A, Lazar MA. Induction of Rev-ErbA alpha, an orphan receptor encoded on the opposite strand of the alpha-thyroid hormone receptor gene, during adipocyte differentiation. J Biol Chem. 1993;268:16265–16269.PubMedGoogle Scholar
  58. 58.
    Rey G, Cesbron F, Rougemont J, Reinke H, Brunner M, Naef F. Genome-wide and phase-specific DNA-binding rhythms of BMAL1 control circadian output functions in mouse liver. PLoS Biol. 2011;9:e1000595.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Lande-Diner L, Boyault C, Kim JY, Weitz CJ. A positive feedback loop links circadian clock factor CLOCK–BMAL1 to the basic transcriptional machinery. Proc Natl Acad Sci USA. 2013;110:16021–16026.PubMedCrossRefGoogle Scholar
  60. 60.
    Peliciari-Garcia RA, Previde RM, Nunes MT, Young ME. Interrelationship between 3,5,3-triiodothyronine and the circadian clock in the rodent heart. Chronobiol Int. 2016;33:1444–1454.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Lightman SL, Conway-Campbell BL. The crucial role of pulsatile activity of the HPA axis for continuous dynamic equilibration. Nat Rev Neurosci. 2010;11:710–718.PubMedCrossRefGoogle Scholar
  62. 62.
    Droste SK, de Groote L, Atkinson HC, Lightman SL, Reul JM, Linthorst AC. Corticosterone levels in the brain show a distinct ultradian rhythm but a delayed response to forced swim stress. Endocrinology. 2008;149:3244–3253.PubMedCrossRefGoogle Scholar
  63. 63.
    Conway-Campbell BL, Pooley JR, Hager GL, Lightman SL. Molecular dynamics of ultradian glucocorticoid receptor action. Mol Cell Endocrinol. 2012;348:383–393.PubMedCrossRefGoogle Scholar
  64. 64.
    Surjit M, Ganti KP, Mukherji A, et al. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell. 2011;145:224–241.PubMedCrossRefGoogle Scholar
  65. 65.
    So AY, Bernal TU, Pillsbury ML, Yamamoto KR, Feldman BJ. Glucocorticoid regulation of the circadian clock modulates glucose homeostasis. Proc Natl Acad Sci USA. 2009;106:17582–17587.PubMedCrossRefGoogle Scholar
  66. 66.
    Conway-Campbell BL, Sarabdjitsingh RA, McKenna MA, et al. Glucocorticoid ultradian rhythmicity directs cyclical gene pulsing of the clock gene period 1 in rat hippocampus. J Neuroendocrinol. 2010;22:1093–1100.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Torra IP, Tsibulsky V, Delaunay F, et al. Circadian and glucocorticoid regulation of Rev-erbalpha expression in liver. Endocrinology. 2000;141:3799–3806.PubMedCrossRefGoogle Scholar
  68. 68.
    de Guia RM, Rose AJ, Herzig S. Glucocorticoid hormones and energy homeostasis. Hormone Mol Biol Clin Investig. 2014;19:117–128.Google Scholar
  69. 69.
    Dourakis SP, Sevastianos VA, Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol. 2002;97:1074–1075.PubMedCrossRefGoogle Scholar
  70. 70.
    Matsumoto T, Yamasaki S, Arakawa A, et al. Exposure to a high total dosage of glucocorticoids produces nonalcoholic steatohepatitis. Pathol Int. 2007;57:388–389.PubMedCrossRefGoogle Scholar
  71. 71.
    Woods CP, Hazlehurst JM, Tomlinson JW. Glucocorticoids and nonalcoholic fatty liver disease. J Steroid Biochem Mol Biol. 2015;154:94–103.PubMedCrossRefGoogle Scholar
  72. 72.
    Dijk DJ, Czeisler CA. Paradoxical timing of the circadian rhythm of sleep propensity serves to consolidate sleep and wakefulness in humans. Neurosci Lett. 1994;166:63–68.PubMedCrossRefGoogle Scholar
  73. 73.
    Dijk DJ, Czeisler CA. Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. J Neurosci. 1995;15:3526–3538.PubMedCrossRefGoogle Scholar
  74. 74.
    Stephan FK, Zucker I. Circadian rhythms in drinking behavior and locomotor activity of rats are eliminated by hypothalamic lesions. Proc Natl Acad Sci USA. 1972;69:1583–1586.PubMedCrossRefGoogle Scholar
  75. 75.
    Nagai K, Nishio T, Nakagawa H, Nakamura S, Fukuda Y. Effect of bilateral lesions of the suprachiasmatic nuclei on the circadian rhythm of food-intake. Brain Res. 1978;142:384–389.PubMedCrossRefGoogle Scholar
  76. 76.
    Shimba S, Ishii N, Ohta Y, et al. Brain and muscle Arnt-like protein-1 (BMAL1), a component of the molecular clock, regulates adipogenesis. Proc Natl Acad Sci USA. 2005;102:12071–12076.PubMedCrossRefGoogle Scholar
  77. 77.
    Turek FW, Joshu C, Kohsaka A, et al. Obesity and metabolic syndrome in circadian clock mutant mice. Science (New York, NY). 2005;308:1043–1045.CrossRefGoogle Scholar
  78. 78.
    Marcheva B, Ramsey KM, Buhr ED, et al. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature. 2010;466:627–631.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Shimba S, Ogawa T, Hitosugi S, et al. Deficient of a clock gene, brain and muscle Arnt-like protein-1 (BMAL1), induces dyslipidemia and ectopic fat formation. PLoS ONE. 2011;6:e25231.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Shi SQ, Ansari TS, McGuinness OP, Wasserman DH, Johnson CH. Circadian disruption leads to insulin resistance and obesity. Curr Biol CB. 2013;23:372–381.PubMedCrossRefGoogle Scholar
  81. 81.
    Husse J, Hintze SC, Eichele G, Lehnert H, Oster H. Circadian clock genes Per1 and Per2 regulate the response of metabolism-associated transcripts to sleep disruption. PLoS ONE. 2012;7:e52983.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Ford ES, Li C, Wheaton AG, Chapman DP, Perry GS, Croft JB. Sleep duration and body mass index and waist circumference among U.S. adults. Obesity (Silver Spring, MD). 2014;22:598–607.CrossRefGoogle Scholar
  83. 83.
    Elder BL, Ammar EM, Pile D. Sleep duration, activity levels, and measures of obesity in adults. Public Health Nurs (Boston, MA). 2016;33:200–205.CrossRefGoogle Scholar
  84. 84.
    Fatima Y, Doi SA, Mamun AA. Longitudinal impact of sleep on overweight and obesity in children and adolescents: a systematic review and bias-adjusted meta-analysis. Obes Rev. 2015;16:137–149.PubMedCrossRefGoogle Scholar
  85. 85.
    Rao MN, Neylan TC, Grunfeld C, Mulligan K, Schambelan M, Schwarz JM. Subchronic sleep restriction causes tissue-specific insulin resistance. J Clin Endocrinol Metabol. 2015;100:1664–1671.CrossRefGoogle Scholar
  86. 86.
    Cappuccio FP, D’Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2010;33:414–420.PubMedCrossRefGoogle Scholar
  87. 87.
    Mullington JM, Simpson NS, Meier-Ewert HK, Haack M. Sleep loss and inflammation. Best Pract Res Clin Endocrinol Metab. 2010;24:775–784.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Itani O, Kaneita Y, Tokiya M, et al. Short sleep duration, shift work, and actual days taken off work are predictive life-style risk factors for new-onset metabolic syndrome: a seven-year cohort study of 40,000 male workers. Sleep Med. 2017;39:87–94.PubMedCrossRefGoogle Scholar
  89. 89.
    Kim CW, Yun KE, Jung HS, et al. Sleep duration and quality in relation to nonalcoholic fatty liver disease in middle-aged workers and their spouses. J Hepatol. 2013;59:351–357.PubMedCrossRefGoogle Scholar
  90. 90.
    Miyake T, Kumagi T, Furukawa S, et al. Short sleep duration reduces the risk of nonalcoholic fatty liver disease onset in men: a community-based longitudinal cohort study. J Gastroenterol. 2015;50:583–589.PubMedCrossRefGoogle Scholar
  91. 91.
    Miyake T, Kumagi T, Hirooka M, et al. Significance of exercise in nonalcoholic fatty liver disease in men: a community-based large cross-sectional study. J Gastroenterol. 2015;50:230–237.PubMedCrossRefGoogle Scholar
  92. 92.
    Liu C, Zhong R, Lou J, et al. Nighttime sleep duration and risk of nonalcoholic fatty liver disease: the Dongfeng–Tongji prospective study. Ann Med. 2016;48:468–476.PubMedCrossRefGoogle Scholar
  93. 93.
    Rybnikova NA, Haim A, Portnov BA. Does artificial light-at-night exposure contribute to the worldwide obesity pandemic? Int J Obes. 2016;40:815–823.CrossRefGoogle Scholar
  94. 94.
    Weingarten JA, Collop NA. Air travel: effects of sleep deprivation and jet lag. Chest. 2013;144:1394–1401.PubMedCrossRefGoogle Scholar
  95. 95.
    Fowler PM, McCall A, Jones M, Duffield R. Effects of long-haul transmeridian travel on player preparedness: case study of a national team at the 2014 FIFA World Cup. J Sci Med Sport. 2017;20:322–327.PubMedCrossRefGoogle Scholar
  96. 96.
    Roenneberg T, Allebrandt KV, Merrow M, Vetter C. Social jetlag and obesity. Curr Biol CB. 2012;22:939–943.PubMedCrossRefGoogle Scholar
  97. 97.
    Parsons MJ, Moffitt TE, Gregory AM, et al. Social jetlag, obesity and metabolic disorder: investigation in a cohort study. Int J Obes. 2015;39:842–848.CrossRefGoogle Scholar
  98. 98.
    Hung HC, Yang YC, Ou HY, Wu JS, Lu FH, Chang CJ. The relationship between impaired fasting glucose and self-reported sleep quality in a Chinese population. Clin Endocrinol. 2013;78:518–524.CrossRefGoogle Scholar
  99. 99.
    Hung HC, Yang YC, Ou HY, Wu JS, Lu FH, Chang CJ. The association between self-reported sleep quality and overweight in a Chinese population. Obesity (Silver Spring, MD). 2013;21:486–492.CrossRefGoogle Scholar
  100. 100.
    Tasali E, Leproult R, Ehrmann DA, Van Cauter E. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci USA. 2008;105:1044–1049.PubMedCrossRefGoogle Scholar
  101. 101.
    Della Monica C, Johnsen S, Atzori G, Groeger JA, Dijk DJ. Rapid eye movement sleep, sleep continuity and slow wave sleep as predictors of cognition, mood, and subjective sleep quality in healthy men and women, aged 20–84 years. Front Psychiatry. 2018;9:255.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Stamatakis KA, Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal subjects. Chest. 2010;137:95–101.PubMedCrossRefGoogle Scholar
  103. 103.
    Hara R, Wan K, Wakamatsu H, et al. Restricted feeding entrains liver clock without participation of the suprachiasmatic nucleus. Genes Cells Devot Mol Cell Mech. 2001;6:269–278.CrossRefGoogle Scholar
  104. 104.
    Birketvedt GS, Sundsfjord J, Florholmen JR. Hypothalamic–pituitary–adrenal axis in the night eating syndrome. Am J Physiol Endocrinol Metab. 2002;282:E366–E369.PubMedCrossRefGoogle Scholar
  105. 105.
    Gallant AR, Lundgren J, Drapeau V. The night-eating syndrome and obesity. Obes Rev. 2012;13:528–536.PubMedCrossRefGoogle Scholar
  106. 106.
    Stunkard AJ, Grace WJ, Wolff HG. The night-eating syndrome: a pattern of food intake among certain obese patients. Am J Med. 1955;19:78–86.PubMedCrossRefGoogle Scholar
  107. 107.
    Bernsmeier C, Weisskopf DM, Pflueger MO, et al. Sleep disruption and daytime sleepiness correlating with disease severity and insulin resistance in nonalcoholic fatty liver disease: a comparison with healthy controls. PLoS ONE. 2015;10:e0143293.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Salgado-Delgado RC, Saderi N, Basualdo Mdel C, Guerrero-Vargas NN, Escobar C, Buijs RM. Shift work or food intake during the rest phase promotes metabolic disruption and desynchrony of liver genes in male rats. PLoS ONE. 2013;8:e60052.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Salgado-Delgado R, Angeles-Castellanos M, Saderi N, Buijs RM, Escobar C. Food intake during the normal activity phase prevents obesity and circadian desynchrony in a rat model of night work. Endocrinology. 2010;151:1019–1029.PubMedCrossRefGoogle Scholar
  110. 110.
    Donga E, van Dijk M, van Dijk JG, et al. A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. J Clin Endocrinol Metabol. 2010;95:2963–2968.CrossRefGoogle Scholar
  111. 111.
    Shan Z, Ma H, Xie M, et al. Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care. 2015;38:529–537.PubMedCrossRefGoogle Scholar
  112. 112.
    Lin D, Sun K, Li F, et al. Association between habitual daytime napping and metabolic syndrome: a population-based study. Metab Clin Exp. 2014;63:1520–1527.PubMedCrossRefGoogle Scholar
  113. 113.
    Fang W, Li Z, Wu L, et al. Longer habitual afternoon napping is associated with a higher risk for impaired fasting plasma glucose and diabetes mellitus in older adults: results from the Dongfeng–Tongji cohort of retired workers. Sleep Med. 2013;14:950–954.PubMedCrossRefGoogle Scholar
  114. 114.
    Baoying H, Hongjie C, Changsheng Q, et al. Association of napping and night-time sleep with impaired glucose regulation, insulin resistance and glycated haemoglobin in Chinese middle-aged adults with no diabetes: a cross-sectional study. BMJ Open. 2014;4:e004419.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Leite NC, Villela-Nogueira CA, Pannain VL, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011;31:700–706.PubMedCrossRefGoogle Scholar
  116. 116.
    Lamia KA, Storch KF, Weitz CJ. Physiological significance of a peripheral tissue circadian clock. Proc Natl Acad Sci USA. 2008;105:15172–15177.PubMedCrossRefGoogle Scholar
  117. 117.
    Kalsbeek A, La Fleur S, Van Heijningen C, Buijs RM. Suprachiasmatic GABAergic inputs to the paraventricular nucleus control plasma glucose concentrations in the rat via sympathetic innervation of the liver. J Neurosci. 2004;24:7604–7613.PubMedCrossRefGoogle Scholar
  118. 118.
    Cailotto C, La Fleur SE, Van Heijningen C, et al. The suprachiasmatic nucleus controls the daily variation of plasma glucose via the autonomic output to the liver: are the clock genes involved? Eur J Neurosci. 2005;22:2531–2540.PubMedCrossRefGoogle Scholar
  119. 119.
    Rudic RD, McNamara P, Curtis AM, et al. BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. PLoS Biol. 2004;2:e377.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Zhang EE, Liu Y, Dentin R, et al. Cryptochrome mediates circadian regulation of cAMP signaling and hepatic gluconeogenesis. Nat Med. 2010;16:1152–1156.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Organization WH. Obesity and Overweight. 2016; http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed September 26, 2017.
  122. 122.
    Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, MD). 2016;64:73–84.CrossRefGoogle Scholar
  123. 123.
    Hasler G, Buysse DJ, Klaghofer R, et al. The association between short sleep duration and obesity in young adults: a 13-year prospective study. Sleep. 2004;27:661–666.PubMedCrossRefGoogle Scholar
  124. 124.
    Vioque J, Torres A, Quiles J. Time spent watching television, sleep duration and obesity in adults living in Valencia, Spain. Int J Obes Relat Metab Disorders. 2000;24:1683–1688.CrossRefGoogle Scholar
  125. 125.
    Kripke DF, Garfinkel L, Wingard DL, Klauber MR, Marler MR. Mortality associated with sleep duration and insomnia. Arch Gen Psychiatry. 2002;59:131–136.PubMedCrossRefGoogle Scholar
  126. 126.
    Schmid SM, Hallschmid M, Jauch-Chara K, et al. Short-term sleep loss decreases physical activity under free-living conditions but does not increase food intake under time-deprived laboratory conditions in healthy men. Am J Clin Nutr. 2009;90:1476–1482.PubMedCrossRefGoogle Scholar
  127. 127.
    Capers PL, Fobian AD, Kaiser KA, Borah R, Allison DB. A systematic review and meta-analysis of randomized controlled trials of the impact of sleep duration on adiposity and components of energy balance. Obes Rev. 2015;16:771–782.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Calvin AD, Carter RE, Adachi T, et al. Effects of experimental sleep restriction on caloric intake and activity energy expenditure. Chest. 2013;144:79–86.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Spaeth AM, Dinges DF, Goel N. Resting metabolic rate varies by race and by sleep duration. Obesity (Silver Spring, MD). 2015;23:2349–2356.CrossRefGoogle Scholar
  130. 130.
    Karlsson B, Knutsson A, Lindahl B. Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27,485 people. Occup Environ Med. 2001;58:747–752.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Samblas M, Milagro FI, Mansego ML, Marti A, Martinez JA. PTPRS and PER3 methylation levels are associated with childhood obesity: results from a genome-wide methylation analysis. Pediatr Obes. 2017;13:149–158.PubMedCrossRefGoogle Scholar
  132. 132.
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231.PubMedCrossRefGoogle Scholar
  133. 133.
    Ahmed MH, Byrne CD. Obstructive sleep apnea syndrome and fatty liver: association or causal link? World J Gastroenterol. 2010;16:4243–4252.PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with nonalcoholic fatty liver disease: a cross-sectional study. J Hepatol. 2009;50:1029–1034.PubMedCrossRefGoogle Scholar
  135. 135.
    Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:1741–1747.PubMedCrossRefGoogle Scholar
  136. 136.
    Hsieh SD, Muto T, Murase T, Tsuji H, Arase Y. Association of short sleep duration with obesity, diabetes, fatty liver and behavioral factors in Japanese men. Intern Med (Tokyo, Japan). 2011;50:2499–2502.CrossRefGoogle Scholar
  137. 137.
    Imaizumi H, Takahashi A, Tanji N, et al. The association between sleep duration and nonalcoholic fatty liver disease among Japanese men and women. Obes Facts. 2015;8:234–242.PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Trovato FM, Martines GF, Brischetto D, Catalano D, Musumeci G, Trovato GM. Fatty liver disease and lifestyle in youngsters: diet, food intake frequency, exercise, sleep shortage and fashion. Liver Int. 2016;36:427–433.PubMedCrossRefGoogle Scholar
  139. 139.
    Katsagoni CN, Georgoulis M, Papatheodoridis GV, et al. Associations between lifestyle characteristics and the presence of nonalcoholic fatty liver disease: a case–control study. Metab Syndr Relat Disorders. 2017;15:72–79.CrossRefGoogle Scholar
  140. 140.
    Katsagoni CN, Papatheodoridis GV, Papageorgiou MV, et al. A “healthy diet-optimal sleep” lifestyle pattern is inversely associated with liver stiffness and insulin resistance in patients with nonalcoholic fatty liver disease. Appl Physiol Nutr Metab. 2017;42:250–256.PubMedCrossRefGoogle Scholar
  141. 141.
    Balakrishnan M, El-Serag HB, Kanwal F, Thrift AP. Shiftwork is not associated with increased risk of NAFLD: findings from the national health and nutrition examination survey. Dig Dis Sci. 2017;62:526–533.PubMedCrossRefGoogle Scholar
  142. 142.
    Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.PubMedPubMedCentralCrossRefGoogle Scholar
  143. 143.
    Qu H, Wang H, Deng M, Wei H, Deng H. Associations between longer habitual day napping and nonalcoholic fatty liver disease in an elderly Chinese population. PLoS ONE. 2014;9:e105583.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Mwangi SM, Nezami BG, Obukwelu B, et al. Glial cell line-derived neurotrophic factor protects against high-fat diet-induced obesity. Am J Physiol Gastrointest Liver Physiol. 2014;306:G515–G525.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Satoh Y, Kawai H, Kudo N, Kawashima Y, Mitsumoto A. Time-restricted feeding entrains daily rhythms of energy metabolism in mice. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1276–R1283.PubMedCrossRefGoogle Scholar
  146. 146.
    Yanagihara H, Ando H, Hayashi Y, Obi Y, Fujimura A. High-fat feeding exerts minimal effects on rhythmic mRNA expression of clock genes in mouse peripheral tissues. Chronobiol Int. 2006;23:905–914.PubMedCrossRefGoogle Scholar
  147. 147.
    Bray MS, Young ME. Diurnal variations in myocardial metabolism. Cardiovasc Res. 2008;79:228–237.PubMedCrossRefGoogle Scholar
  148. 148.
    Kohsaka A, Laposky AD, Ramsey KM, et al. High-fat diet disrupts behavioral and molecular circadian rhythms in mice. Cell Metab. 2007;6:414–421.PubMedCrossRefGoogle Scholar
  149. 149.
    Hsieh MC, Yang SC, Tseng HL, Hwang LL, Chen CT, Shieh KR. Abnormal expressions of circadian-clock and circadian clock-controlled genes in the livers and kidneys of long-term, high-fat-diet-treated mice. Int J Obes. 2010;34:227–239.CrossRefGoogle Scholar
  150. 150.
    Djouadi F, Weinheimer CJ, Saffitz JE, et al. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice. J Clin Investig. 1998;102:1083–1091.PubMedCrossRefGoogle Scholar
  151. 151.
    Patel DD, Knight BL, Wiggins D, Humphreys SM, Gibbons GF. Disturbances in the normal regulation of SREBP-sensitive genes in PPAR alpha-deficient mice. J Lipid Res. 2001;42:328–337.PubMedGoogle Scholar
  152. 152.
    Montagner A, Polizzi A, Fouche E, et al. Liver PPARalpha is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut. 2016;65:1202–1214.PubMedPubMedCentralCrossRefGoogle Scholar
  153. 153.
    Stienstra R, Mandard S, Patsouris D, Maass C, Kersten S, Muller M. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology. 2007;148:2753–2763.PubMedCrossRefGoogle Scholar
  154. 154.
    Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology (Baltimore, MD). 2003;38:123–132.CrossRefGoogle Scholar
  155. 155.
    Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology (Baltimore, MD). 2004;39:1286–1296.CrossRefGoogle Scholar
  156. 156.
    Kettner NM, Voicu H, Finegold MJ, et al. Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis. Cancer Cell. 2016;30:909–924.PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an american academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2017;13:307–349.PubMedPubMedCentralCrossRefGoogle Scholar
  158. 158.
    Irwin MR, Cole JC, Nicassio PM. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol. 2006;25:3–14.PubMedCrossRefGoogle Scholar
  159. 159.
    Srinivasan V, Singh J, Pandi-Perumal SR, Brown GM, Spence DW, Cardinali DP. Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs. Adv Therapy. 2010;27:796–813.CrossRefGoogle Scholar
  160. 160.
    Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag. 2011;7:577–584.PubMedPubMedCentralGoogle Scholar
  161. 161.
    Goyal A, Terry PD, Superak HM, et al. Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial. Diabetol Metab Syndr. 2014;6:124.PubMedPubMedCentralCrossRefGoogle Scholar
  162. 162.
    Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr (Edinburgh, Scotland). 2017.  https://doi.org/10.1016/j.clnu.2017.12.004.CrossRefGoogle Scholar
  163. 163.
    Gonciarz M, Gonciarz Z, Bielanski W, et al. The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. J Physiol Pharmacol. 2012;63:35–40.PubMedGoogle Scholar
  164. 164.
    Gonciarz M, Gonciarz Z, Bielanski W, et al. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin. J Physiol Pharmacol. 2010;61:705–710.PubMedGoogle Scholar
  165. 165.
    Hirota T, Lee JW, St John PC, et al. Identification of small molecule activators of cryptochrome. Science (New York, NY). 2012;337:1094–1097.CrossRefGoogle Scholar
  166. 166.
    Lee JW, Hirota T, Kumar A, Kim NJ, Irle S, Kay SA. Development of small-molecule cryptochrome stabilizer derivatives as modulators of the circadian clock. ChemMedChem. 2015;10:1489–1497.PubMedPubMedCentralCrossRefGoogle Scholar
  167. 167.
    Shah YM, Morimura K, Yang Q, Tanabe T, Takagi M, Gonzalez FJ. Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol. 2007;27:4238–4247.PubMedPubMedCentralCrossRefGoogle Scholar
  168. 168.
    Cariou B, Staels B. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. Expert Opin Investig Drugs. 2014;23:1441–1448.PubMedCrossRefGoogle Scholar
  169. 169.
    Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and nonalcoholic fatty liver disease. Expert Opin Pharmacother. 2014;15:493–503.PubMedCrossRefGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2018

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyMedical University of South CarolinaCharlestonUSA
  2. 2.Division of Gastroenterology and HepatologyUniversity Hospital EssenEssenGermany
  3. 3.Section of GastroenterologyRalph H Johnson Veterans Affairs Medical CenterCharlestonUSA

Personalised recommendations